Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7530793 | 0.89 | LMNA (0.80) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL1200313 | 0.89 | HPGD (0.80) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL1199530 | 0.89 | LMNA (0.79) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL1199804 | 0.88 | HPGD (0.78) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL2750244 | 0.88 | LMNA (0.78) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL1199098 | 0.88 | LMNA (0.78) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL532885 | 0.87 | LMNA (0.78) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL1199332 | 0.86 | LMNA (0.76) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL2747919 | 0.85 | LMNA (0.74) | LMNAHPGDTSHRALDH1A1NPSR1 | |
| SCHEMBL2748676 | 0.85 | HPGD (0.74) | LMNAHPGDTSHRALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034702-B2 | Thienoisoquinolines and their derivatives for the treatment of cancer | Valorbec, Société en commandite (CA) | 2021-06-15 | — | — | US | disclosed |
| US-11034702-B2 | Thienoisoquinolines and their derivatives for the treatment of cancer | Valorbec, Société en commandite (CA) | 2021-06-15 | — | — | US | disclosed |
| US-20200276181-A1 | THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR TARGETING TUBULIN, CH-TOG, AURORA A KINASE, TPX2, CDK5RAP2 AND/OR ASPM | VALORBEC, SEC (CA) | 2020-09-03 | — | — | US | disclosed |
| US-20200276181-A1 | THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR TARGETING TUBULIN, CH-TOG, AURORA A KINASE, TPX2, CDK5RAP2 AND/OR ASPM | VALORBEC, SEC (CA) | 2020-09-03 | — | — | US | disclosed |
| EP-3551636-A1 | THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR THE TREATMENT OF CANCER | Valorbec, Société en Commandite (CA) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018102920-A1 | THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR THE TREATMENT OF CANCER | VALORBEC, SEC (CA) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018102920-A1 | THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR THE TREATMENT OF CANCER | VALORBEC, SEC (CA) | 2018-06-14 | — | — | WO | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20010051614-A1 | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | LEVIN JEREMY IAN (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1147102-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6200996-B1 | ARTHRITIS; BONE, GASTROINTESTINAL DISORDERS; CROHN*S DISEASE, MULTIPLE SCLEROSIS | AMERICAN CYANAMID COMPANY | 2001-03-13 | — | — | US | disclosed |
| US-6197795-B1 | ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; WOUND HEALING AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6162814-A | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2000-12-19 | — | — | US | disclosed |
| US-6162821-A | Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000044740-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5962481-A | ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; WOUND HEALING AGENTS;ANTIULCER AGENTS; ORAL DISEASES; CENTRAL NERVOUS SYTEM DISORDERS; ANTIINFLAMMATORY AGENTS; CONGESTIVE HEART FAILURE;VISION DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0934300-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998016520-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034702-B2 | Thienoisoquinolines and their derivatives for the treatment of cancer | CSPP1, TUBB, PLK1 | LMNA 1621/4885HPGD 3462/4885TSHR 3221/4885 |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | CCR9, CCR1, CCR10 | LMNA 4182/4885HPGD 2182/4885TSHR 518/4885 |
| US-20010051614-A1 | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MMP1, MMP12, MMP26 | LMNA 3281/4885HPGD 2404/4885TSHR 508/4885 |
| US-20200276181-A1 | THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR TARGETING TUBULIN, CH-TOG, AURORA A KINASE, TPX2, CDK5RAP2 AND/OR ASPM | AURKA, AURKC, AURKB | LMNA 2931/4885HPGD 3665/4885TSHR 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.